Research : Literature

Publications in Journals with Peer-Review


  1. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz H-J, Lappegard K, Seifried E, Scharrer I, Tuddenham EGD, Müller CR, Strom TM, Oldenburg J (2004) Mutations in the VKORC1 gene cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537-41. (IF 27,96 mit Editorial von E. Sadler)
  2. Watzka M, Geisen C, Seifried E, Oldenburg J (2004) Sequence of the rat factor VIII cDNA. Thromb Haemost 91:38-42 (IF 4.910)
  3. Schneppenheim R, Lenk H, Obser T, Oldenburg J, Oyen F, Schneppenheim S, Schwaab R, Will K, Budde U (2004) Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization. Thromb Haemost: in press
  4. Rost S, Fregin A, Koch D, Compes M, Müller CR, Oldenburg J (2004) Compound heterozygous mutations in the Gamma-Glutamyl-Carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors. Br J Haematol: in press


  5. Srour MA, Fechner H, Wang X, Siemetzki U, Albert T, Oldenburg J, Hanfland P, Poller W, Brackmann HH, Schwaab R (2003) Regulation of human factor IX expression using doxycycline-inducible gene expression system. Thromb Haemost 90:398-405 (IF 4.910)
  6. El-Maarri O, Seoud M, Coullin P, Herbiniaux U, Oldenburg J, Rouleau G, Slim R (2003) Maternal alleles acquiring paternal methylation patterns in biparental complete hydatidiform moles. Hum Mol Genet 15:1405-1413 (IF 9,318)
  7. Oldenburg J, Schroeder J, Graw J, Ivaskevicius V, Brackmann HH, Schramm W, Muller CR, Seifried E, Schwaab R (2003) Significance of mutation analysis in patients with haemophilia A. Hämostaseologie 23:6-12 (IF N.N.)
  8. Uen C, Oldenburg J, Schroder J, Brackmann HJ, Schramm W, Schwaab R, Schneppenheim R, Graw J (2003) 2% Haemophilia A patients without mutation in the FVIII gene. Hämostaseologie 23:1-5 (IF N.N.)
  9. Albert T, Lange S, Oldenburg J, Graw J, Schramm W, Hanfland P, Brackmann HH, Schwaab R (2003) Characterization of factor VIII antibody epitopes from haemophilia A patients using cellulose bound FVIII peptide libraries. Hämostaseologie 23:13-17 (IF N.N.)
  10. Krebs H, Domsch C, Adelhard K, Brackmann HH, Graw J, Oldenburg J, Schwaab R, Schramm W (2003) The national GTH haemophilia registry as database within the scope of the German human genome project. Hämostaseologie 23:18-23 (IF N.N.)
  11. Brackmann HH, Albert T, Graw J, Oldenburg J, Schramm W, Schwaab R (2003) Gathering and evaluation of phenotype data of haemophilia A patients for correlation with genotype data. Hämostaseologie 23:24 (IF N.N.)
  12. Hofer A, Hermans M, Kubassek N, Sitzer M, Funke H, Stogbauer F, Ivaskevicius V, Oldenburg J, Burtscher J, Knopp U, Schoch B, Wanke I, Hubner F, Deinsberger W, Meyer B, Boecher-Schwarz H, Poewe W, Raabe A, Steinmetz H, Auburger G (2003) Elastin polymorphism haplotype and intracranial aneurysms are not associated in central Europe. Stroke 34:1207-1211 (IF 5.330)


  13. Fregin A, Rost S, Wolz W, Krebsova A, Mueller CR, Oldenburg J (2002) Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors (FMFD) to the centromeric region of chromosome 16. Blood 100:3329-3332 (IF 9.273)
  14. Klopp N, Oldenburg J, Uen C, Schneppenheim R, Graw J (2002) 11 haemophilia A patients without mutations in the FVIII encoding gene. Thromb Haemost 88:357-360 (IF 4.910)
  15. Kreuz W, Leissinger C, Oldenburg J, Lusher J, Kelleher J, Gorina E, Kellermann E, Larson P. (2002) Inhibitor development and FVIII gene mutation analysis in a pediatric cohort treated with sucrose formulated, full-length recombinant Factor VIII. Haemophilia 8:836 (IF 0.756)
  16. Kreuz W, Ettingshausen CE, Zyschka A, Oldenburg J, Saguer IM, Ehrenforth S, Klingebiel T (2002) Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost 28:285-90 (IF 2.147)
  17. Brackmann HH, Effenberger W, Schwaab R, Hess L, Hanfland P, Oldenburg J (2002) Quality management and quality assurance in haemophilia care: a model at the Bonn haemophilia centre. Haemophilia 8:211-216 (IF 0.756)
  18. El-Maarri O, Herbiniaux U, Walter J, Oldenburg J (2002) A rapid, quantitative, non-radioactive bisulfite-SNuPE-IP RP HPLC assay for methylation analysis at specific CpG sites. Nucl Acid Res 30:e25 (IF 9.900)


  19. Leuer M*, Oldenburg J*, Lavergne JM, Ludwig M, Fregin A, Eigel A, Ljung R, Goodeve A, Peake I, Olek K (2001) Somatic mosaicism in hemophilia A: A fairly common event. Am J Hum Genet 69:75-87 (*contributed equally) (IF 10.542)
  20. Neuhaus T, Hertfelder HJ, Hess L, Oldenburg J, Walger P, Vetter H (2001) An uncommon cause of severe soft tissue bleeding during phenprocoumon treatment. Dtsch Med Wochenschr 126:654-756 (IF 0.704)
  21. Oldenburg J (2001) Mutation profiling in Haemophilia A. Thromb Haemost 85: 577-579 (IF 4.910)
  22. Ivaskevicius V, Jurgutis R, Rost S, Müller A, Schmitt C, Wulff K, Herrmann FH, Müller CR, Schwaab R, Oldenburg J (2001) Lithuanian haemophilia A and B register comprising phenotypic and genotypic data. Br J Haematol 112:1062-1070 (IF 2.815)
  23. Schneppenheim R, Budde U, Obser T, Brassard J, Krey S, Mainusch K, Ruggeri ZM, Schwaab R, Oldenburg J (2001) Expression and characterization of von Willebrand dimerization defects in different types of von Willebrand disease. Blood 97:2059-2066 (IF 9.273)
  24. Oldenburg J, Kriz K, Wuillemin WA, Maly FE, Felten von A, Siegemund A, Keeling DM, Baker P, Chu K, Konkle B, Lämmle B, Albert T (2001) Genetic predisposition to bleeding during oral anticoagulant therapy: Evidence for common founder mutations (FIXVal-10 and FIXThr-10) and an independent CpG hotspot mutation (FIXThr-10). Thromb Haemost 85:454-457 (IF 4.910)
  25. Bestmann L, Züger M, Oldenburg J, Bühler D, Maly FE (2001) LightCycler PCR for coagulation factor IX propeptide Alanine-10 - Valine and Alanine-10 - Threonine mutations causing coumarin hypersensitivity: Identification of two female Alanine-10 - Valine heterozygotes in an affected family. Thromb Haemost 85:567-568 (IF 4.910)
  26. Oldenburg J, Ivaskevicius V, Rost S, Fregin A, White K, Holinski-Feder E, Müller CR, Weber BHF (2001) Evaluation of DHPLC in the analysis of haemophilia A. J Biochem Biophys Methods 47:39-51 (IF 1.118)


  27. Oldenburg J, Brederlow von B, Fregin A, Rost S, Wolz W, Eberl W,Eber S, Lenz E, Schwaab R, Brackmann HH, Effenberger W, Harbrecht U, Schurgers L, Vermeer C, Müller CR (2000) Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a defect of the vitamin K-epoxide-reductase-complex. Thromb Haemost 84:937-941 (IF 4.910)
  28. Oldenburg J, Rost S, El-Maarri O, Leuer M, Olek K, Müller CR, Schwaab R (2000) De novo factor VIII intron 22 inversion in a female carrier presents as a somatic mosaicism. Blood 96:2905-2906 (IF 9.273)
  29. Schwaab R, Oldenburg J, Kemball-Cook G, Albert T, Johler C, Hanfland P, Ingerslev J (2000) Assay discrepancies in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family. Br J Haematol 109:523-528 (IF 2.815)
  30. Brackmann HH, Effenberger W, Hess R, Schwaab R, Oldenburg J (2000) NovoSeven in immune tolerance therapy. Blood Coagulation and Fibrinolysis 11 (Suppl 1):39-44 (IF I.594)


  31. Lenz E, Repas-Humpe M, Oldenburg J, Kreuz W, Schroter W, Eber SW (1999) Therapy-resistant haemarthros in a patient with factor VIII inhibitor: successful treatment with recombinant factor VIIa. Eur J Pediatr 158:951-952 (IF 1.220)
  32. El-Maarri O, Oldenburg J, Caglayan SH (1999) Intron 22-specific long PCR for the Xba I polymorphism in the factor VIII gene. Br J Haematol; 105:1120-1122 (IF 2.815)
  33. Oldenburg J, Schwaab R, Brackmann HH (1999) Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sang 77 (Suppl 1):49-54 (IF 1.944)
  34. Haack A, Schmitt C, Poller W, Oldenburg J, Hanfland P, Brackmann HH, Schwaab R (1999) Analysis of expression kinetics and activity of a new B-domain truncated and full-length FVIII protein in three different cell lines. Ann Hematol 78:111-116 (IF 1.566)


  35. Rockstroh JK, Reichel C, Hille H, Oldenburg J, Brackmann HH (1998) Pharmacokinetics of azidothymidine and its major metabolite glucuronylazidothymidine in hemophiliacs coinfected with human immunodeficiency virus and chronic hepatitis C. Am J Ther 5:387-391 (IF N.N)
  36. Harbrecht U, Oldenburg J, Klein P, Weber D, Rockstroh J, Hanfland P (1998) Increased sensitivity of FIX to Phenprocoumon as a cause of severe bleeding in a patient with antiphospholipid antibody associated thrombosis. J Int Med 243:73-77 (IF 2.898)
  37. Oldenburg J, Schröder J, Schmitt C, Brackmann HH, Schwaab R (1998) Small deletion / insertion mutations within poly-a runs of the factor VIII gene mitigate the severe haemophilia A phenotype. Thromb Haemost 79:452-453 (IF 4.910)
  38. El-Maarri O, Olek A, Balaban B, Montag M, van der Ven H, Urman B, Olek K, Caglayan SH, Walter J, Oldenburg J (1998) Methylation levels at selected CpG sites in the factor VIII and FGFR3 genes, in mature female and male germ cells: implications for male driven evolution. Am J Hum Genet 63:1001-1008 (IF 10.542)
  39. Brackmann HH, Effenberger W, Hess L, Schwaab R, Oldenburg J (1998) Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)? Eur J Haematol 63 (Suppl):18-23 (IF 1.672)


  40. Oldenburg J, Picard J, Schwaab R, Brackmann HH, Tuddenham EGD, Simpson E (1997) HLA Genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb and Haemost 77:238-242 (IF 4.910)
  41. Bierhoff E, Fischer HP, Willsch E, Rockstroh J, Spengler U, Brackmann HH, Oldenburg J (1997) Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection. Virchows Arch 430:271-277 (IF 1.709)
  42. Quenzel EM, Hertfelder HJ, Oldenburg J (1997) Severe bleeding in two patients due to increased sensitivity of factor IX activity to phenprocoumon therapy. Annals of Hematology 74:265-268 (IF 1.566)
  43. Oldenburg J, Quenzel EM, Harbrecht U, Fregin A, Kress W, Müller CR, Hertfelder HJ, Schwaab R, Brackmann HH, Hanfland P (1997) Missense mutation at Ala-10 in the factor IX-propeptide: An insignificant variant in normall life but a decisive cause for bleeding during oral anticoagulant therapy. Brit J Haematol 98:240-244 (IF 2.815)
  44. Oldenburg J, Harbrecht U (1997) RE: Should patients starting anticoagulant therapy be screened for missense mutations at Ala-10 in the factor IX propeptide? Br J Haematol 99:468 (IF 2.815)
  45. Schwaab R, Oldenburg J, Lalloz MRA, Schwaab U, Pemberton S, Hanfland P, Brackmann HH, Tuddenham EGD, Michaelides K (1997) Factor VIII gene mutations found by a comparative study of SSCP, DGGE and CMC and their analysis on a molecular model of factor VIII protein. Hum Gen 101:323-332 (IF 3.209)


  46. Brackmann HH, Oldenburg J, Schwaab R (1996) Immune tolerance for the treatment of factor VIII inhibitors - ‘Twenty years Bonn Protocol`. Vox Sanguinis 70 (Suppl 1):30-35 (IF 1.944)
  47. Becker J, Schwaab R, Möller-Taube A, Schwaab U, Schmidt W, Brackmann HH, Grimm T, Olek K, Oldenburg J (1996) Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: Family studies indicate a mutation type dependent sex ratio of mutation frequencies. Am J Hum Genet 58:657-670 (IF 10.542)
  48. Eis-Hübinger AM, Oldenburg J, Brackmann HH, Matz B, Schneweis KE (1996) The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population. Zbl Bakt 284:232-240 (IF 0.538)
  49. Schneppenheim R, Budde U, Krey S, Drewke E, Bergmann F, Lechler E, Oldenburg J, Schwaab R (1996) Results of screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease Type 1. Thromb Haemost 76:598-602 (IF 4.910)
  50. Rockstroh JK, Spengler U, Sudhop T, Ewig S, Theisen A, Hammerstein U, Bierhoff E, Fischer HP, Oldenburg J, Brackmann HH, Sauerbruch T (1996) Immunosuppression may lead to progression of Hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterology 91:2563-2568 (IF 3.549)


  51. Rockstroh JK, Ewig S, Bauer T, Lüchters G, Oldenburg J, Bailly E, Kaiser R, Schneweis KE, Brackmann HH, Dengler J, Sauerbruch T (1995) Male-to-female transmission of HIV in a cohort of hemophiliacs - frequency, risk factors and effect of sexual counseling. Infection 23:29-32 (IF 1.250)
  52. Schwaab R, Oldenburg J, Schwaab U, Johnson DJ, Schmidt W, Olek K, Brackmann HH, Tuddenham EG (1995) Characterization of mutations within the factor VIII gene of 73 unrelated mild and moderate haemophiliacs. Br J Haematol 91:458-64 (IF 2.815)
  53. Kasper P, Simmonds P, Schneweis KE, Kaiser R, Matz B, Oldenburg J, Brackmann HH, Holmes EC (1995) The genetic diversification of the HIV type 1 Gag p17 gene in patients infected from a common source. AIDS Res Hum Retroviruses 11:1197-1201 (IF 2.523)
  54. Kupfer B, Oldenburg J, Brackmann HH, Matz B, Schneweis KE, Kaiser R (1995) ß-Propiolactone UV-inactivated clotting factor concentrate is the source of HIV-infection in 8 haemophilia B patients: confirmed. Thromb Haemost 74:1386-1387 (IF 4.910)
  55. Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EGD, Oldenburg J (1995) Haemophilia A: Mutation type determines risk of inhibitor formation. Throm Haemost 74:1402-1406 (IF 4.910)
  56. Oldenburg J, Effenberger W, Hammerstein U, Brackmann HH (1995) Report on experiences with two recombinant factor VIII concentrates: Kogenate (Bayer) and Recombinate (Baxter). Infusionsther Transfusionsmed 22 (Suppl):60-62 (IF 0.359)
  57. Brackmann HH, Gomperts ED, Courter SC, Vidor A, O'Brian S, Oldenburg J (1995) Long term surveillance for human anti-mouse antibodies of a group of hemophiliacs treated only with immunaffinity purified VIII concentrates. Haemophilia 1:111-114 (IF 0.756)


  58. Brackmann HH, Oldenburg J, Eis-Hübinger AM, Gerritzen A, Hammerstein U, Hanfland P (1994) Hepatitis A virus infection among the Hemophilia population at the Bonn Hemophilia Center. Vox Sang 67 (Suppl 1):3-8 (IF 1.944)
  59. Nägele M, Kunze V, Hamann M, Eickoff H, Koch W, Oldenburg J, Reiser M, Steudel A (1994) Hemophiliac arthropathy of the knee joint. Gd-DTPA-enhanced MRI; Clinical and roentgenological Correlation. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 160:154-158 (IF 1.454)
  60. Rosanowski F, Walther EK, Rockstroh J, Hück P, Oldenburg J (1994) HIV- assoziierte parotiszysten. Laryngo-Rhino-Otol 73:215-218 (IF 0.447)
  61. Kochhan L, Lalloz MRA, Oldenburg J, McVey JH, Olek K, Brackmann HH, Tuddenham EGD, Schwaab R (1994) Detection of 10 factor VIII intron 13 dinuleotide repeat alleles using a fluorescent dye-labelled oligonucleotide. Blood Coagulation and Fibrinolysis 5: 497-501 (IF 1.594)


  62. Große-Bley A, Eis-Hübinger AM, Kaiser R, Oldenburg J, Brackmann HH, Schwarz TF, Schneweis KE (1993) Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs. Thromb Haemost 72:503-507 (IF 4.910)
  63. Kasper P, Kaiser R, Oldenburg J, Brackmann HH, Matz B, Schneweis KE (1994) Parallel evolution in the V3 region of HIV-1 after infection of hemophiliacs from a common source. Aids Res and Hum Retrovir 12:1669-1678 (IF 2.523)
  64. Kasper P, Kaiser R, Kleim JP, Oldenburg J, Brackmann HH, Rockstroh J, Schneweis KE (1993) Diversification of HIV-1 strains after infection from a unique source. Aids Res and Hum Retrovir 9:153-157 (IF 2.523)
  65. Brackmann SA, Gerritzen A, Oldenburg J, Brackmann HH, Schneweis KE (1993) Search for intrafamilial transmission of Hepatitis C virus in hemophilia patients. Blood 81:1077-1082 (IF 9.273)
  66. Schwaab R, Oldenburg J, Tuddenham EGD, Brackmann HH, Olek K (1993) Mutations in Haemophilia A. Brit J Haematology 83:450-458 (IF 2.815)
  67. Brackmann HH, Aygören E, Scharrer I, Hammerstein U, Oldenburg J (1993) Two years expierience with two recombinant factor VIII concentrates. Blood Coagulation and Fibrinolysis 4:421-424 (IF 1.594)
  68. Oldenburg J, Schwaab R, Grimm T, Zerres K, Hakenberg P, Brackmann HH, Olek K (1993) Direct and indirect estimation of the sex ratio of mutation frequencies in hemophilia A. Am J Hum Genet 53:1229-1238 (IF 10.542)


  69. Brackmann HH, Eickhoff HJ, Oldenburg J, Hammerstein U (1992) Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience. Haemostasis 22:251-258 (IF 1.325)
  70. Gerritzen A, Schneweis KE, Brackmann HH, Oldenburg J, Hanfland P, Gerlich WH, Caspari G (1992) Acute Hepatitis A in haemophiliacs. Lancet 340:1231-1232 (IF 13.251)
  71. Gerritzen A, Scholt B, Schneweis KE Brackmann HH, Oldenburg J (1992) Acute Hepatitis C in haemophiliacs due to "virus-inactivated" clotting factor concentrates. Thromb Haemost 68:781 (IF 4.910)


  72. Schwaab R, Ludwig M, Kochhan L, Oldenburg J, McVey JH, Egli H, Brackmann HH, Olek K (1991) Detection and characterisation of two missense mutations at a cleaveage site in the factor VIII light chain. Thromb Res 61:225-234 (IF 1.446)
  73. Higuchi M, Antonarakis SE, Kasch L, Oldenburg J, Economou-Petersen E, Olek K, Arai M, Inaba H, Kazazian HH (1991) Molecular characterization of mild-to-moderate hemophilia A: Detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis. Proc Natl Acad Sci USA 88: 8307-8311 (IF 10.896)


  74. Schwaab R, Ludwig M, Oldenburg J, Brackmann HH, Egli H, Kochhan L, Olek K (1990) Identical point mutations in the factor VIII gene that have different clinical manifestations in hemophilia A. Am J Hum Genet 47:743-744 (IF 10.542)
  75. Kleim JP, Bailly E, Schneweis KE, Brackmann HH, Hammerstein U, Hanfland P, Loo van B, Oldenburg J (1990) Acute HIV-1 infection in patients with hemophilia B treated with ß- propiolactone-UV-inactivated clotting factor. Thromb Haemost 64:336-337 (IF 4.910)


  76. Schwaab R, Oldenburg J, Higuchi M, Ludwig M, Kochhan L, Horst J, Brackmann HH, Egli H, Olek K (1988) Haemophilia A: Carrier detection by DNA analysis. Blut 57:85-90 (IF 1.566)


  1. Oldenburg J, Ananyeava NM, Saenko EL (2004) Molecular basis in haemophilia A. State of the Art. Haemophilia: in press (IF 0.756)
  2. Saint-Remy JM, Lacroix-Desmazes S, Oldenburg J (2004) Inhibitors in haemophilia: pathophysiology. State of the Art. Haemophilia: in press (IF 0.756)
  3. Oldenburg J, Ivaskevicius V, Schröder J, Brackmann HH, Müller CR, Schwaab R, Seifried E, Tuddenham E (2004) Haemophilia A: Role of genetic defect, race and environmental factors in inhibitor development. J Thromb Thrombolys (Supple): in press (IF 1.055)
  4. Oldenburg J, Schröder J, Brackmann HH, Müller CR, Schwaab R, Tuddenham E (2004) Environmental and genetic factors influencing inhibitor development. Semin Hematol 41(1 Suppl):82-88 (IF 2.147)
  5. Hess L, Zeitler H, Unkrig Ch, Nettekoven W, Albert T, Schwaab R, Effenberger W, Oldenburg J, Vetter H, Hanfland P, Brackmann HH (2003) Modified Bonn-Malmö Protocol (MBM-P). Haematologica 88 (Suppl. 12): 78-85 (IF 3.216)
  6. Oldenburg J, El-Maarri O, Schwaab R (2002) Inhibitor development in correlation to factor VIII genotypes. Haemophilia 8:23-9 (IF 0.756)
  7. Oldenburg J, Schwaab R (2001) Molecular biology of coagulation factors. Semin Thromb Hemost 27:313-324 (IF 2.147)
  8. Schwaab R, Oldenburg J (2001) Gene therapy of hemophilia. Semin Thromb Hemost 27: 417-424 (IF 2.147)
  9. Oldenburg J, Brackmann HH, Schwaab R (2000) Risk factors for inhibitor development in haemophilia A. Haematologica (suppl)85: 7-14 (IF 3.216)
  10. Brackmann HH, Schwaab R, Effenberger W, Hess L, Hanfland P, Oldenburg J (2000) Side effects during immune tolerance induction. Haematologica (suppl) 85:75-77 (IF 3.216)
  11. Oldenburg J, Brackmann HH, Hanfland P, Schwaab R (2000) State of the art: molecular genetics in haemophilia A. Vox Sang 78 (suppl 2):33-38 (IF 1.944)
  12. Brackmann HH, Schwaab R, Effenberger W, Hess L, Hanfland P, Oldenburg J (2000) State of the art: Antibodies to factor VIII in haemophilia A patients. Vox Sang 78 (suppl 2):269-272 (IF 1.944)
  13. Schambeck CM, Oldenburg J (2000) The Renaissance of clotting factors - do high levels indicate a higher risk for venous thromboembolism? J Lab Med 24:139-145 (IF 1.992)
  14. Scharrer I, Neutzling O, Schwaab R, Oldenburg J, Ehrlich H (1998) Experiences with recombinant factor VIII products: development of inhibitors and immune tolerance therapy. Ann Hematol 76 (suppl 1):1-6 (IF 1.566)
  15. Oldenburg J, Albert T, Brackmann HH, Schwaab R (1998) Molekulare Grundlagen der Hämophilie A. Hämostaseologie 18:107-120 (IF N.N.)
  16. Oldenburg J, Grimm T, Becker J, Olek K, Brackmann HH, Schwaab R (1997) Mutations in severe Haemophilia A: Distribution in the factor VIII Gene, Origin and influence on inhibitor development. Beitr Infusionsther Transfusionsmed 34: 224-230 (IF 0.359)
  17. Oldenburg J, Hertfelder HJ, Brackmann HH, Trobisch H, Hanfland P (1996) Eigenschaften und Indikationen von PPSB-Konzentrat unter besonderer Berücksichtigung der Qualitätssicherung sowie flankierender therapeutischer Maßnahmen. Infusionsther Transfusionsmed 23:271-280 (IF 0.359)
  18. Schwaaab R, Oldenburg J, Brackmann HH., Hanfland P (1994) Hämophilie A: Molekularbiologie und überträgerdiagnose. Infusionsther Transfusionsmed 21: 116-125 (IF 0.359)

Book chapters

  1. Oldenburg J, Tuddenham EGD (2004) Inhibitors to Factor VIII: Molecular Basis. In Textbook of Hemophilia. Editors: Lee CA, Koots K, Berntorp E. Blackwell Science Oxford: in press
  2. El-Maarri O, Küpper M, Oldenburg J, WalterJ (2004) Quantitative DNA-methylation analysis by the bisulfite conversion method. In: PCR Technology, Current Innovations, 2nd edition. Editors Weissensteiner T, Griffin HG, Griffin A. CRC Press 2004:175-186
  3. Seifried E, Oldenburg J (2004) Angeborene plasmatische Gerinnungsstörungen einschliesslich Von-Willebrand-Syndrom. In: Transfusionsmedizin, 3. Auflage. Hrsg. Müller-Eckhardt C. Springer Verlag:410-428
  4. El-Maarri O, Oldenburg J, WalterJ (2003) SIRPH: a rapid. Quantitative SbuPE-IP RP HPLC method for simultaneous methylation analysis at multiple CpG sites. In: Genetic variance detection, Nuts & Bolts of DHPLC in Genomics. Editor Hecker KH. Xela Schenk ISBN: 0-9664027-7-4: 151-162
  5. Oldenburg J, Schwaab R (2003) Molekularbiologie angeborener Gerinnungsstörungen. In: Klinische Anwendung plasmatischer und rekombinanter Gerinnungsfaktoren. Hrsg. Brackmann H-H, Schwaab R, Oldenburg J, Schramm W. UniMed Verlag:34-51
  6. Oldenburg J, Riess H (2003) Hereditäre hämorrhagische Diathesen. In: Rationelle Diagnostik und Therapie in der Inneren Medizin. Hrsg. Classen M, Dierkesmann R, Heimpel H, Koch K-M, Meyer J, Müller OA, Specker CH, Theiss W. Für die Deutsche Gesellschaft für Innere Medizin. Lieferung 13, Urban und Fischer Verlag 2002: Kapitel B27
  7. Oldenburg J, Schröder J, Ivaskevicius V, Graw J, Brackmann HH, Schramm W, Seifried E, Schwaab R, Müller-Reible CR (2002) Large scale mutation profiling on haemophilia A - A joint cooperation within the frame of the German Human Genome Project. In: Gene Diagnosis of Inherited Bleeding Disorders. Editor Herrmann FH. Pabst Science Publishers:53-76
  8. Oldenburg J, Tuddenham EGD (2002) Genetic basis of inhibitor development in severe haemophilia A and B. In: Inhibitors in Patients with Haemophilia. Editors Rodriguez-Merchan EC and Lee CA. Blackwell Science Oxford:21-28
  9. Oldenburg J, Brackmann HH, Schwaab R (1999) Genetic predisposition to inhibitor development in haemophilia A. In: Molekulare (DNA) Diagnostik hereditärer Hämostasedefekte. Hrsg. Herrmann FH. Pabst Science Publishers:43-52
  10. Oldenburg J, Brackmann HH, Schwaab R (1998) Predisposing factors on inhibitor formation in haemophilia A patients. In: Molecular Biology and Immunology in Haemophilia A. Editor Brackmann HH. Die Medizinische Verlagsgesellschaft Umwelt und Medizin mbH:27-37
  11. Oldenburg J, Hertfelder HJ, Brackmann HH, Trobisch H, Hanfland P (1998) Therapie mit PPSB-Konzentraten. In: Hämostaseologie. Hrsg. Müller-Berghaus/Pötzsch. Springer Verlag:740-748
  12. Oldenburg J, Brackmann HH, Olek K, Schwaab-R (1998) Hämophilie A: Konduktorinnen- und Pränataldiagnostik. In: Hämostaseologie. Hrsg. Müller-Berghaus/ Pötzsch. Springer Verlag:207-215
  13. Schwaab R, Brackmann HH, Oldenburg J (1998) Spektrum molekulargenetischer Methoden zur Untersuchung von hereditären Hämostasestörungen. In: Häemostaseologie. Hrsg. Müller-Berghaus/Pötzsch. Springer Verlag:216-227
  14. Seuser A, Oldenburg J, Brackmann H H (1998) Pathogenese, Diagnose und orthopädische Therapie der hämophilen Gelenkarthropathie. In: Hämostaseologie. Hrsg. Müller-Berghaus/Pötzsch. Springer Verlag:198-206
  15. Oldenburg J, Brackmann HH (1998) Diagnostik, Pathogenese und Klinik der Hämophilie A und B. In: Hämostaseologie. Hrsg. Müller-Berghaus/Pötzsch. Springer Verlag:185-197